Búsqueda del medicamento por su nombre

Azulfidine Tablets y Disfuncion renal

Resultado de la verificación de la interacción del medicamento Azulfidine Tablets y la enfermedad de Disfuncion renal en la seguridad cuando se comparte.

Resultado de la verificación:

Azulfidine Tablets <> Disfuncion renal

Relevancia: 23.07.2019 Examinador: P.M. Shkutko, M.D., in

Al verificar la interacción según fuentes acreditadas Drugs.com, Rxlist.com, Webmd.com, Medscape.com contraindicaciones o efectos secundarios se han encontrado que pueden causar daño o aumentar el efecto negativo cuando el medicamento se usa con esta enfermedad concomitante.

Consumidor:

Las sulfonamidas y sus metabolitos se eliminan por el riñón. Los pacientes con insuficiencia renal pueden estar en mayor riesgo de efectos adversos de sulfonamidas debido a la disminución de la eliminación del fármaco. Ajustes de la dosis puede ser necesario y modificaciones deben ser basadas en el grado de disfunción renal y la severidad de la infección. Además, las sulfonamidas pueden causar toxicidad renal secundaria a crystalluria, incluyendo uro - y litiasis renal, nefritis, tóxicos nefrosis, hematuria, proteinuria y elevación de BUN y creatinina. Hidratación (8 oz. vaso de agua con cada dosis y durante todo el día) y una adecuada producción de orina (> 1,5 L/día) debe ser mantenida durante sulfonamida de la administración. Pruebas de función Renal y análisis de orina debe realizarse semanalmente o con la frecuencia indicada por el estado del paciente. Rara vez, la alcalinización de la orina es necesario.

Fuentes

Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979): s371-81
Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985): 535-9
Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M "Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man." J Pharm Sci 61 (1972): 773-8
Finland M, Strauss E, Peterson O "Sulfadiazine." JAMA 251 (1984): 1467-74
Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970): 561-6
Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975): 171-9
Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970): 250-4
Rieder J, Schwartz DE, Fernex M, et al "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974): 148-98
Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982): 22-118
Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979): s382-7
Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981): 350-7
Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992): 361
Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994): 1605-6
Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980): 405-23
Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972): 483-92
Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979): s382-7
Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987): 81-5
Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988): 483-8
Boisvert A, Barbeau G, Belanger PM "Pharmacokinetics of sulfisoxazole in young and elderly subjects." Gerontology 30 (1984): 125-31
"Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn, Kalamazoo, MI.
Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987): 783-4
Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973): 383-7
Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992): 1006-7
Gleckman R, Gantz NM, Joubert DW "Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions." Pharmacotherapy 1 (1981): 206-11
Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989): 85-6
Molina J, Belenfant X, Doco-Lecompte T, et al "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991): 587-9
"Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.
Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993): 365-7
Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992): 739-40
Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993): 254-6
"Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc, Laurelton, NY.
Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985): 285-302
"Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories, Nutley, NJ.
Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966): 1-9
Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996): 185-94
Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980): 360-1
Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982): 461-70
Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988): 791-2
Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990): 233-4
Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992): 361
Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979): s367-70
Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988): 72-5
Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974): 112-7
Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978): 57-67
Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972): 539-51
Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990): 2379-84
Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973): 703-12
Mannisto PT, Mantyla R, Mattila J, Nykanen S, Lamminsivu U "Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion." J Antimicrob Chemother 9 (1982): 461-70

Azulfidine Tablets

Nombre genérico: sulfasalazine

Marca comerciale: Azulfidine, Azulfidine EN-tabs, Sulfazine

Sinónimos: Azulfidine

¿Qué es Azulfidine Tablets?

Otro medicamento Eliminar

Azulfidine Tablets <> Disfuncion renal

Relevancia: 23.07.2019 Examinador: P.M. Shkutko, M.D., in

Consumidor:

El uso de este medicamento y otros compuestos que contengan o se convierten en mesalamina raramente se ha asociado con insuficiencia renal efectos adversos, incluyendo un cambio mínimo nefropatía aguda y crónica, nefritis intersticial, y la diabetes insípida nefrógena. Las lesiones renales tales como infarto renal, necrosis papilar, tubular, necrosis y fibrosis intersticial se han reportado en altas dosis en estudios con animales. La terapia con mesalamina y profármacos de este medicamento debe ser administrado con precaución en pacientes con deterioro de la función renal o antecedentes de enfermedad renal. La función Renal debe ser evaluada antes del inicio del tratamiento y periódicamente durante el tratamiento.

Fuentes

"Product Information. Pentasa Product Information (mesalamine)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442
Masson EA, Rhodes JM "Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss." Gut 33 (1992): 563-4
"Product Information. Asacol product information (mesalamine)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.
"Product Information. Dipentum (olsalazine)." Meda Pharmaceuticals, Somerset, NJ.
"Product Information. Rowasa product information (mesalamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
Thuluvath PJ, Ninkovic M, Calam J, Anderson M "Mesalazine induced interstitial nephritis." Gut 35 (1994): 1493-6
Mehta RP "Acute interstitial nephritis due to 5-aminosalicylic acid." Can Med Assoc J 143 (1990): 1031-2
Wilcox GM, Reynolds JR, Galvanek EG "Nephrotoxicity associated with olsalazine." Am J Med 100 (1996): 238-40
"Product Information. Colazal (balsalazide)" Salix Pharmaceuticals, Palo Alto, CA.

Azulfidine Tablets

Nombre genérico: sulfasalazine

Marca comerciale: Azulfidine, Azulfidine EN-tabs, Sulfazine

Sinónimos: Azulfidine

¿Qué es Azulfidine Tablets?

Otro medicamento Eliminar

Lista de interacciones frecuentes